| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 2206.4 | 2026.3 | 1653.5 |
| Other income | 13.0 | 9.2 | 27.0 |
| Total income | 2219.4 | 2035.5 | 1680.4 |
| Profit before exceptional items & tax | 591.8 | 481.4 | 269.7 |
| Profit before tax | 591.8 | 481.4 | 269.7 |
| Net profit | 436.2 | 362.1 | 194.5 |
| Operating margin | 26.7% | 23.7% | 16.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +124.30% |
|---|---|
| Net profit, quarter on quarter | +20.50% |
| Revenue, year on year | +33.40% |
| Operating profit, year on year | +138.50% |
| Operating profit, quarter on quarter | +22.60% |
NSE results filing, NSE: LAURUSLABS. Figures extracted from the filing.
Laurus Labs Ltd: key numbers
- Share price
- ₹2,170.00
- Market cap
- ₹1,17,248 Cr
- Revenue (annual)
- ₹6,813 Cr
- Net profit (annual)
- ₹888.8 Cr
- P/E (TTM)
- 107.2×Sector 46.1×
- Promoter holding
- 27.47%+0.00% QoQ
- FII holding
- 30.84%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Laurus Labs Ltd
All →Laurus Labs Results Update
Laurus Labs reported H1 FY27 revenue of ₹4,233 Cr and EBITDA of ₹1,406 Cr. The company acquired Galenvs Sciences and SI&C Resins to expand CDMO capabilities.
- SPPS peptide synthesis capacity
- 16000 L
Laurus Labs Investor Presentation: Key Takeaways
Q2/H1 FY27: H1 revenue ₹4,233 Cr (+31%), EBITDA ₹1,406 Cr (33.2% margin), PAT ₹809 Cr (+126%). CDMO-led growth; ₹3,000 Cr+ capex planned FY27-28.
Laurus Labs Dividend
Laurus Labs approved a Re. 1.00 per share interim dividend for FY 2026-27. Record date is November 6, 2026; payment on or after November 19, 2026.
Laurus Labs Management Change
Laurus Labs appointed Mr. Kundan Kumar Jha as Joint Company Secretary effective November 1, 2026, following Board approval. The KMP appointment advances the company's succession planning process.
Laurus Labs Acquisition Worth ₹32.5 Cr
Laurus Labs approved acquiring 52% of SI & C Resins for Rs. 32.50 Crore. The acquisition makes SI&C a subsidiary for peptide resin manufacturing.
- Value
- ₹32.50 Cr
Laurus Labs Acquisition Worth ₹35.63 Cr
Laurus Labs approved buying 60% of Canada-based CRO Galenvs Sciences for USD 3.75 million (₹35.63 Cr). The deal adds an oligonucleotide R&D arm and North American presence.
- Value
- ₹35.63 Cr